Display options
Cite
Zhang KL, Sun Y, Li Y, et al. Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china. Transl Oncol. 2008;1(1):28-35doi: 10.1593/tlo.07103.
Zhang, K. L., Sun, Y., Li, Y., Liu, M., Qu, B., Cui, S. H., Kong, Q. Y., Chen, X. Y., Li, H., & Liu, J. (2008). Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china. Translational oncology, 1(1), 28-35. https://doi.org/10.1593/tlo.07103
Zhang, Kai-Li, et al. "Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china." Translational oncology vol. 1,1 (2008): 28-35. doi: https://doi.org/10.1593/tlo.07103
Zhang KL, Sun Y, Li Y, Liu M, Qu B, Cui SH, Kong QY, Chen XY, Li H, Liu J. Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china. Transl Oncol. 2008 Mar;1(1):28-35. doi: 10.1593/tlo.07103. PMID: 18607505; PMCID: PMC2510761.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2008 Mar;1(1):28-35. doi: 10.1593/tlo.07103.

Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of china.

Translational oncology

Kai-Li Zhang, Yuan Sun, Yan Li, Ming Liu, Bo Qu, Shu-Hong Cui, Qing-You Kong, Xiao-Yan Chen, Hong Li, Jia Liu

Affiliations

  1. Department of Cell Biology and Liaoning Laboratory of Cancer Genomics, College of Basic Medical Sciences, Dalian Medical University, Dalian 116027, PR China.

PMID: 18607505 PMCID: PMC2510761 DOI: 10.1593/tlo.07103

Abstract

This study aimed to profile the methylation statuses of CDH1/E-cadherin and five CpG island methylator phenotype (CIMP)-associated genes (p16, hMLH1, MINT1, MINT2, and MINT31) in gastric specimens of 47 Dalian long-term residents with and 31 without gastric cancers (GCs). CIMP patterns were classified as CIMP-H with over three methylated genes, CIMP-L with one to two methylated genes, and CIMP-N without methylation. Of 47 GC cases, 24 (51.1%) were CIMP-H, 18 (38.3%) were CIMP-L, and 5 (10.6%) were CIMP-N, whereas 5 of 21 (23.8%) premalignant lesions were CIMP-H and 15 (71.4%) were CIMP-L. CIMP-L was found in 75% (12/16) of GC-adjacent mucosa and in 38.7% (12/31) of mucosa from GC-free patients. CDH1 methylation occurred in 48.9% (23/47) of cancer, in 23.8% (5/21) of premalignant, and in 25% (4/16) of noncancerous tissues and was correlated with patients' age (P = .01), lymph node metastasis, and CIMP severity (P = .000-.028). Our results demonstrated that the frequencies of CIMP-H in Dalian GCs, CIMP-L, and p16 methylation in GC-adjacent tissues and in GC-free mucosa were much higher than those reported previously, indicating the elevated methylation pressure in this GC high-risk region. The close correlation between CDH1 methylation and CIMP severity suggests the necessity of their combination in GC prevention and earlier diagnosis.

References

  1. Nat Rev Cancer. 2004 Dec;4(12):988-93 - PubMed
  2. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 - PubMed
  3. Ann N Y Acad Sci. 2006 Sep;1076:810-21 - PubMed
  4. Cell Res. 2005 Apr;15(4):247-54 - PubMed
  5. Am J Pathol. 2002 Mar;160(3):787-94 - PubMed
  6. Mutat Res. 1992 Feb;265(2):211-21 - PubMed
  7. Cancer Detect Prev. 2006;30(2):168-73 - PubMed
  8. J Biol Chem. 2004 Nov 5;279(45):46384-92 - PubMed
  9. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  10. Int J Cancer. 2007 Feb 1;120(3):656-63 - PubMed
  11. J Natl Cancer Inst. 2002 May 15;94(10):755-61 - PubMed
  12. Cell Cycle. 2004 May;3(5):611-5 - PubMed
  13. Toxicol Appl Pharmacol. 2006 Nov 1;216(3):458-68 - PubMed
  14. Am J Pathol. 2003 Mar;162(3):815-22 - PubMed
  15. Hum Pathol. 2006 Dec;37(12):1557-67 - PubMed
  16. Clin Cancer Res. 2006 May 15;12(10):2995-3002 - PubMed
  17. Ann Oncol. 2004 Mar;15(3):489-92 - PubMed
  18. Trends Genet. 1997 Aug;13(8):335-40 - PubMed
  19. Cancer Res. 1999 Nov 1;59(21):5438-42 - PubMed
  20. BMC Cancer. 2006 Aug 23;6:212 - PubMed
  21. Int J Mol Med. 2003 Sep;12(3):299-304 - PubMed
  22. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 - PubMed
  23. Cancer Res. 1999 Apr 1;59(7):1572-7 - PubMed
  24. Cancer Res. 2001 Apr 1;61(7):2847-51 - PubMed
  25. Clin Exp Metastasis. 2005;22(1):85-93 - PubMed
  26. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 - PubMed
  27. Lab Invest. 2003 Apr;83(4):519-26 - PubMed
  28. Cancer Res. 1988 Jun 15;48(12):3518-23 - PubMed
  29. Cancer Res. 2006 Nov 1;66(21):10621-9 - PubMed
  30. Hum Pathol. 2006 Aug;37(8):989-99 - PubMed
  31. Int J Oncol. 2004 Apr;24(4):1039-47 - PubMed
  32. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11995-9 - PubMed
  33. N Engl J Med. 2003 Nov 20;349(21):2042-54 - PubMed
  34. Oncogene. 2004 Jun 3;23(26):4646-54 - PubMed
  35. Int J Cancer. 2002 Dec 20;102(6):623-8 - PubMed
  36. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):989-95 - PubMed
  37. Hum Mol Genet. 2000 Oct;9(16):2395-402 - PubMed
  38. Am J Pathol. 2003 Oct;163(4):1551-6 - PubMed
  39. Cell. 1992 Jul 10;70(1):5-8 - PubMed
  40. Cell Microbiol. 2003 Nov;5(11):821-34 - PubMed

Publication Types